KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Cash from Financing Activities (2016 - 2025)

Boston Scientific (BSX) has disclosed Cash from Financing Activities for 17 consecutive years, with -$184.0 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities fell 185.98% to -$184.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$395.0 million through Dec 2025, down 121.78% year-over-year, with the annual reading at -$395.0 million for FY2025, 121.78% down from the prior year.
  • Cash from Financing Activities hit -$184.0 million in Q4 2025 for Boston Scientific, down from -$104.0 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $1.6 billion in Q1 2024 to a low of -$344.0 million in Q2 2022.
  • Historically, Cash from Financing Activities has averaged $39.0 million across 5 years, with a median of $1.5 million in 2021.
  • Biggest five-year swings in Cash from Financing Activities: crashed 17300.0% in 2022 and later surged 2373.91% in 2024.
  • Year by year, Cash from Financing Activities stood at -$8.0 million in 2021, then soared by 112.5% to $1.0 million in 2022, then surged by 1400.0% to $15.0 million in 2023, then skyrocketed by 1326.67% to $214.0 million in 2024, then plummeted by 185.98% to -$184.0 million in 2025.
  • Business Quant data shows Cash from Financing Activities for BSX at -$184.0 million in Q4 2025, -$104.0 million in Q3 2025, and -$340.0 million in Q2 2025.